Arrowhead Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Arrowhead Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 92% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 90% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Sep 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-1.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 61% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
$30Sales grew 241% in 3 years; of every extra $100 of sales, $30 became extra profit.
Higher than 57% of Healthcare companies in United States.
Asset Productivity Ratio
+241% / +100%In 3 years sales changed by +241% while total assets changed by +100%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
4.5×Debt due within a year is covered 4.5 times by its yearly operating cash.
Higher than 79% of Healthcare companies in United States.
Cash Cushion Ratio
+7%Cash, after subtracting all debt, equals 7% of its market value (net cash).
Lower than 54% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 92% of Healthcare companies in United States.
Tangible Net Worth Ratio
99%Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 90% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Arrowhead Pharmaceuticals, Inc. made a loss over the last year. Arrowhead Pharmaceuticals, Inc. owes $0.78 for every $1 it owns. Arrowhead Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Sep 2025.
P/E ratio
LossArrowhead Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
17.71The share price is 17.71 times Arrowhead Pharmaceuticals, Inc.'s book value per share, higher than 93% of Healthcare companies in United States.
Market cap
$8.2 BThe total market value of all of Arrowhead Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 88% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$466 MWhat Arrowhead Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.30Net worth divided by the number of shares. The share price of $58.36 is 17.7 times this, which is the P/B above.
Return on equity (ROE)
-55.2%Arrowhead Pharmaceuticals, Inc. lost 55.2% of its shareholders' money over the last year, lower than 54% of Healthcare companies in United States.
Owes vs Owns
0.78×Arrowhead Pharmaceuticals, Inc. owes $0.78 for every $1 it owns (moderate), higher than 76% of Healthcare companies in United States.
Dividend yield
NoneArrowhead Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+23258%Revenue rose 23258% in the year to Sep 2025, and grew 51% a year on average over 3 years.
Profit growth
LossArrowhead Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-0.2%Arrowhead Pharmaceuticals, Inc. lost $0 for every $100 of revenue.
Interest cover
1.1×Arrowhead Pharmaceuticals, Inc.'s operating profit covered its interest costs 1.1 times in the year to Sep 2025.
Cash vs debt
Net cashArrowhead Pharmaceuticals, Inc. held $553 M more cash than debt (net cash) at Sep 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Arrowhead Pharmaceuticals, Inc.: $8.2 B ÷ $466 M (30 Jun 2026) = 17.7.
What is Arrowhead Pharmaceuticals, Inc.'s return on equity?
Arrowhead Pharmaceuticals, Inc. lost 55.2% of its shareholders' money over the last year, lower than 54% of Healthcare companies in United States.
How much does Arrowhead Pharmaceuticals, Inc. owe compared with what it owns?
Arrowhead Pharmaceuticals, Inc. owes $0.78 for every $1 it owns (moderate), higher than 76% of Healthcare companies in United States.
Does Arrowhead Pharmaceuticals, Inc. pay a dividend?
No. Arrowhead Pharmaceuticals, Inc. does not currently pay a dividend.
Is Arrowhead Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 23258% in the year to Sep 2025, and grew 51% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.